Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
cannabis  company  development  marketwired nov  marketwired november  marketwired  medical  nov  november  research  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Thu, 23 Nov 2017 02:33:21 EST

Copyright: Copyright: (C) Marketwired
 



Angle PLC Announces Collaboration With Philips in Breast and Rectal Cancer

Thu, 23 Nov 2017 02:00:00 EST

GUILDFORD, SURREY--(Marketwired - Nov 23, 2017) - Angle PLC (AIM: AGL) (OTCQX: ANPCY)




U.S. FDA Advisory Panel Meetings: Strategies to Maximize Success, New Webinar Hosted by Xtalks

Wed, 22 Nov 2017 15:47:38 EST

TORONTO, ON--(Marketwired - November 22, 2017) - Often, US Food & Drug Administration (FDA) Advisory Panel meetings are the capstone to what is characteristically a long and arduous medical device development journey. While these meetings typically close with a voting session on a medical device's approvability, recent real-world experiences demonstrate that achieving a favorable set of panel votes does not always guarantee swift FDA approval of the medical device under consideration.




Jacobson Pharma Announces FY2018 Interim Results

Wed, 22 Nov 2017 09:55:24 EST

Realizing Growth Strategies With Both Revenue and Net Profit Up; Declares Interim Dividend of HK0.9 cent per share




Northern Vine Labs Combines the Best of Abattis and Emerald Health -- CFN Media

Wed, 22 Nov 2017 09:53:13 EST

SEATTLE, WA--(Marketwired - Nov 22, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering the partnership between Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF) and Emerald Health Therapeutics Inc. (TSX VENTURE: EMH) (OTCQX: EMHTF) to run Northern Vine Laboratories as a joint venture, which promises to take advantage of a growing market for lab testing and extract products.




Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company

Wed, 22 Nov 2017 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Nov. 22, 2017) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today clarified the proposed term of the transaction contemplated by its recently announced non-binding term sheet with a leading China-based pharmaceutical company pursuant to which, subject to further negotiation and execution of a definitive agreement, the Chinese pharmaceutical company would be granted an exclusive license to commercialize CaPre in certain Asian countries, including China.




ESMO Celebrates Successful Completion Of 3rd ESMO Asia Congress In Singapore

Tue, 21 Nov 2017 21:00:00 EST

The momentum continues as experts around the world gather to advance cancer care




Cannabis Science Finalizes Acquisition of its First PRE ICO Dispensary in Los Angeles, California and Continues Negotiations to Close the Second Los Angeles Area Medical Marijuana Dispensary

Tue, 21 Nov 2017 11:29:51 EST

IRVINE, CA--(Marketwired - Nov 21, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its expansions plans are well underway as it has signed agreements to acquire and officially open the first Cannabis Science PRE ICO Medical Marijuana dispensary, in Los Angeles, California.




The Alliance for Regenerative Medicine Releases Q3 2017 Data Report, Highlighting Sector Trends and Metrics

Tue, 21 Nov 2017 10:57:39 EST

WASHINGTON, DC--(Marketwired - Nov 21, 2017) - The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the third quarter of 2017.




Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors

Tue, 21 Nov 2017 08:30:00 EST

BOSTON, MA--(Marketwired - November 21, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has been appointed Chairman of the Board of Directors. Mr. Geraghty replaces Chau Q. Khuong, who is stepping down from the Board after helping guide Pieris through platform validation and partnerships to its transition into a fully-integrated research and clinical development company.




Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT

Tue, 21 Nov 2017 07:30:00 EST

Company will present on Tuesday, December 5, 2017 at 11:30 a.m. PT (2:30 p.m. ET)




Global Medical Information System: Characteristics & Implementation Approach, New Webinar Hosted by Xtalks

Tue, 21 Nov 2017 07:30:00 EST

TORONTO, ON--(Marketwired - November 21, 2017) - In a live session upcoming on Wednesday, December 6, 2017, Techsol, a global leader in life sciences, will present a webinar that will examine key characteristics of a global medical information management system and the critical factors that drive an optimized implementation and deployment strategy.




When Is Central Imaging Needed in Clinical Trials? New Webinar Hosted by Xtalks

Tue, 21 Nov 2017 07:00:00 EST

TORONTO, ON--(Marketwired - November 21, 2017) - On Wednesday, December 6, 2017 Xtalks will host a webinar that summarizes and highlights the various types of imaging and their role in the clinic and in research, with a perspective on the regulatory aspects that govern its use and practical aspects for pharma, biotech and contract research organizations.




SANUWAVE Health Reports Third Quarter Financial Results and Provides a Business Update

Mon, 20 Nov 2017 18:12:07 EST

SUWANEE, GA--(Marketwired - Nov 20, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) reported financial results for the three and nine months ended September 30, 2017 on November 14 2017 and will provide a business update on a conference call at 10:00AM Eastern Time on Tuesday, November 21, 2017. 




Deciphering the Complexity of the Acute Leukemia Immunological Microenvironment with 3D Biology(TM) Technology, New Webinar Hosted by Xtalks

Mon, 20 Nov 2017 12:07:52 EST

TORONTO, ON--(Marketwired - November 20, 2017) - Join the live session on Tuesday, December 5, 2017 at 12pm EST to learn more about how the combined analysis of SNV, mRNA, and protein expression on the nCounter system enabled a comprehensive characterization of the molecular landscape of leukemia cells. Guest speakers include Doug Hinerfeld, Ph.D., Principal Product Application Scientist at NanoString Technologies, and Sergio Rutella, M.D., Ph.D., Professor of Cancer Immunotherapy, at John van Geest Cancer Research Centre, Nottingham Trent University.




mCig's eHesive Advertising Network Signed an Exclusive Agreement with Hosting Company FlameNetworks

Mon, 20 Nov 2017 09:56:52 EST

LAS VEGAS, NV--(Marketwired - Nov 20, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis markets, announced today that the company has entered into an agreement between OBITX, Inc., formerly known as GigeTech, Inc., a wholly owned subsidiary of MCIG and FlameNetworks to implement the proprietary eHesive Advertising Network with an Exclusive territory as an EU partner.




Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner

Mon, 20 Nov 2017 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Nov. 20, 2017) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the company recently entered into a non-binding term sheet with a leading China-based pharmaceutical company. Completion of the transaction is subject to further negotiation and execution of a definitive agreement, which once signed would grant an exclusive license to the Chinese pharmaceutical company to commercialize CaPre in certain Asian countries, including China. With the high prevalence of hypertriglyceridemia in Asia, this potential partnership presents a significant opportunity for Acasti and CaPre.




Advanced Proteome Therapeutics Expands Antibody-Drug Conjugate Collaboration

Mon, 20 Nov 2017 08:00:00 EST

VANCOUVER, BC--(Marketwired - November 20, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics, is expanding the collaboration with the National Research Council of Canada (NRC) and receiving support from its Industrial Research Assistance Program (NRC IRAP) to conduct key steps in development of APC's novel technology.




SanSal Wellness Holdings, Inc. Positioned to Leverage World-Class Agribusiness and Hemp Cultivation Management and Operations Team

Mon, 20 Nov 2017 08:00:00 EST

FORT LAUDERDALE, FL--(Marketwired - Nov 20, 2017) - SanSal Wellness Holdings, Inc. ("SanSal Wellness" or the "Company") (OTC PINK: SSWH), a vertically-integrated agribusiness focused on producing full spectrum natural phytocannabinoid-rich industrial hemp extracts, today provided shareholders and the investment community with an update detailing its world-class management and operations team.




Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

Mon, 20 Nov 2017 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Nov. 20, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data for its novel covalent EGFR inhibitor were presented at the Society for Neuro-Oncology 22nd Annual Meeting, November 16-19, in San Francisco.




Improving Regulatory and Operational Performance in Orphan Drug Development, a New Webinar Presented by Premier Research and Hosted by Xtalks

Mon, 20 Nov 2017 07:00:00 EST

TORONTO, ON--(Marketwired - November 20, 2017) - Today more than ever, regulatory bodies are providing a progressive platform for rare disease drug development. Extensions to existing regulations and incentives and attempts to reduce orphan drug designation applications provide a collaborative environment for companies developing orphan drugs.




Angle PLC: Holding(s) in Company

Fri, 17 Nov 2017 12:03:26 EST

GUILDFORD, SURREY--(Marketwired - Nov 17, 2017) -  Angle PLC (AIM: AGL) (OTCQX: ANPCY)




CFN Media Exclusive Onsite CEO Interview with Lifestyle Delivery Systems: Up and Running in a $5 Billion Market

Fri, 17 Nov 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Nov 17, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive CEO interview and article covering Lifestyle Delivery Systems Inc. (CSE: LDS) (CNSX: LDS) (LDS.CN) (OTCQB: LDSYF), its new state of the art facility in Adelanto, California, and the potential for the company as California implements new regulations for adult-use of marijuana.




Future Farm Partners with Israeli Company to Develop Elite Cannabis Clones -- CFN Media

Fri, 17 Nov 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Nov 17, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the need to develop a wide variety of standardized cannabis plants for a vast array of potential applications, and the efforts of Future Farm Technologies Inc. (CSE: FFT) (CNSX: FFT) (CN.FFT) (OTCQB: FFRMF) to solve the problem.




Cosmos Holdings, Inc. Announces $3 Million Securities Purchase Agreement With Two Institutional Investors

Thu, 16 Nov 2017 14:01:17 EST

CHICAGO, IL--(Marketwired - Nov 16, 2017) - Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced that it has entered into a $3 million securities purchase agreement with two institutional investors.




The Sequoia Project's Annual Meeting to Draw Health IT Leaders Nationwide to Discuss Data Sharing Progress and the Path Forward

Thu, 16 Nov 2017 09:28:07 EST

Event to be held December 5-6 in Gaylord National Harbor, Maryland




SANUWAVE Health to Host Upcoming Clinical and Science Symposium on Advanced Wound Care

Thu, 16 Nov 2017 09:00:00 EST

SUWANEE, GA--(Marketwired - Nov 16, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) today announces the Company's planned Clinical and Science Symposium on Advanced Wound Care to be held on December 8 and 9, 2017, in Atlanta, GA. This event will gather SANUWAVE's clinical researchers, science advisors, Key Opinion Leaders, and world-wide distributors to discuss extracorporeal shockwave technology as an advanced modality in the wound care field, its current applications in the medical field, and future applications in wound care and other medical needs. Medical professionals and distributors will be attending from Taiwan, Italy, Brazil, and South Korea as well as medical advisors from the U.S. SANUWAVE is pleased to have among its presenters Dr. Maria Siemionow, Professor of Orthopedics and Director of Microsurgery Research at the University of Illinois at Chicago College of Medicine and Dr. Ching-Jen Wang, Professor of Orthopaedic Surgery at the Chang Gung University College of Medicine and Chang Gung Memorial Hospital, Taiwan.




Cannabis Science Set to Launch its Online Community for Doctors, Patients, Industry Professionals Worldwide to Share Experiences and Expertise Using Cannabinoid Therapies for Various Critical Ailments, Palliative Care and Related Information

Thu, 16 Nov 2017 08:05:57 EST

IRVINE, CA--(Marketwired - Nov 16, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is proud to announce that next week the company will release its newest version of the Patient Access Center (PAC), an exclusive online community for social networking and information sharing platform. By bringing together Doctors, Patients, Industry Professionals, Lawyers, Scientists, Civil and Constitutional Rights Activists, Legalization Efforts Groups and many others, we are building a powerful knowledge center of real world data of successful treatment stories, formal clinical study information, to mobilizing large groups for upcoming events, or certain demographics that need help to help effective change for each area of concern or question.




SanSal Wellness Holdings, Inc. Highlights Whole-Plant Hemp Oil Extraction Operations and Growth Opportunities

Thu, 16 Nov 2017 08:00:00 EST

FORT LAUDERDALE, FL--(Marketwired - Nov 16, 2017) - SanSal Wellness Holdings, Inc. ("SanSal Wellness" or the "Company") (OTC PINK: SSWH), a vertically-integrated agribusiness focused on producing full spectrum natural phytocannabinoid-rich industrial hemp extracts, today provided shareholders and the investment community with an update highlighting its current operations, business strategy, and growth opportunities in the rapidly expanding market for industrial hemp and whole-plant hemp oil extracts in the USA and internationally.




BioCorRx Provides Business Update for the Third Quarter of 2017

Thu, 16 Nov 2017 08:00:00 EST

Investor Call to be held on Friday, November 17th at 2:00 PM ET




Zenosense, Inc.: MIDS Hybrid Strip - Successful Initial Test Results

Thu, 16 Nov 2017 07:30:00 EST

VALENCIA, SPAIN--(Marketwired - Nov 16, 2017) - Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS CardiacT, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that its MIDS Medical Limited joint venture ("MML") based at Sci-Tech, Daresbury (UK), has successfully completed initial testing of its "Hybrid Strip" system.




Angle PLC: Total Voting Rights and Covington Subscription

Thu, 16 Nov 2017 04:26:57 EST

GUILDFORD, SURREY--(Marketwired - Nov 16, 2017) - Angle PLC (OTCQX: ANPCY) (AIM: AGL)